This is a preview of subscription content, log in via an institution to check access.
Notes
2016/2017 British pounds
Reference
Fawsitt CG, et al. A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value in Health 22: 693-703, No. 6, Jun 2019. Available from: URL: http://doi.org/10.1016/j.jval.2018.12.011
Rights and permissions
About this article
Cite this article
Shorter DAA therapy cost effective in treatment-naïve patients. PharmacoEcon Outcomes News 831, 29 (2019). https://doi.org/10.1007/s40274-019-6017-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6017-0